Pherecydes Pharma S. A. focuses on developing antimicrobial treatments by leveraging bacteriophage viruses, also known as phages. The company's pipeline includes a range of therapeutic options: phages engineered to combat Staphylococcus aureus in bone/joint and diabetic foot ulcer infections; phages targeting Pseudomonas aeruginosa for complicated urinary tract infections; and phages designed to address Escherichia coli in respiratory tract infections.